Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and provider of regulatory services for rapid diagnostic tests and med-tech, announces the official opening yesterday of its
Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and provider of regulatory services for rapid diagnostic tests and med-tech, announces the official opening yesterday of its
UK Launch of LVOne Stroke Triage Test by UpFront Diagnostics
Abingdon Health plc (AIM: ABDX) has provided an update on its partnership with 4TEEN4 Pharmaceuticals GmbH, focused on the co-development of a companion diagnostic for a potentially life-saving shock therapy.
$2.5m Contract Award for development of clinical self-test
c.US$2m multiplex diagnostic test contract win Development, scale-up and technical transfer for a semi-quantitative, multiplex lateral flow test system
Genedrive® MT-RNR1 ID Kit implemented at Dublin’s Rotunda Hospital
Genedrive PLC (AIM: GDR) shares soared 22% to 1.04p after the diagnostics company confirmed it is in talks with major shareholder David Nugent regarding a potential £1 million loan to
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, notes the fall in the Company’s share price on 13 August 2025 which it believes was connected to postings
Genedrive PLC (AIM: GDR), the developer of rapid genetic testing technology, expects total income for the year ended 30 June to rise to around £1 million, up from £0.5 million
Revenue for FY25 in line with market expectations of £8.6m Continued strong revenue growth anticipated in FY26
c. US$2.5m companion diagnostic test contract win Full CDMO service contract for development, scale-up, technical transfer, manufacture and full regulatory support
Genedrive wins EU approval for rapid genetic test aimed at stroke and heart attack care